You are here

Nat Biotechnol DOI:10.1038/nbt.4239

Intron retention is a source of neoepitopes in cancer.

Publication TypeJournal Article
Year of Publication2018
AuthorsSmart, AC, Margolis, CA, Pimentel, H, He, MXiao, Miao, D, Adeegbe, D, Fugmann, T, Wong, K-K, Van Allen, EM
JournalNat Biotechnol
Date Published2018 Aug 16
ISSN1546-1696
Abstract

We present an in silico approach to identifying neoepitopes derived from intron retention events in tumor transcriptomes. Using mass spectrometry immunopeptidome analysis, we show that retained intron neoepitopes are processed and presented on MHC I on the surface of cancer cell lines. RNA-derived neoepitopes should be considered for prospective personalized cancer vaccine development.

DOI10.1038/nbt.4239
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30114007?dopt=Abstract

Alternate JournalNat. Biotechnol.
PubMed ID30114007
Grant ListR01 CA227388 / CA / NCI NIH HHS / United States